In the United States, American Hearth Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular...
The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system...
Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5. Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibitor...
A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular...
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause. Menopause can accelerate age-related weight gain and increase the likelihood of...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led...
A new study from a poison control center in Alabama offers a reassuring perspective on the rising number of calls related to popular GLP-1 receptor agonists, such as Ozempic and Wegovy. While exposures to these medications have increased significantly over the past two decades, the research suggests many cases are accidental, associated with mild symptoms,...
In the United States, American Hearth Month is observed in February to raise awareness about cardiovascular disease, the leading cause of death worldwide. To a similar end, Endocrine News focuses on a few recent journal studies that take a closer look at the impacts of incretin-based therapies in the setting of obesity and impaired cardiovascular...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
